In as early as 2018, a rocket carrying cargo that includes 24 microfluidic chips about the size of credit cards will transport an extraordinary University of Washington kidney research project to the International Space Station (page 4).
ALUMNI LIKE YOU CONTINUE TO LEAD IN GIVING BACK AND BUILDING COMMUNITY. This year, Pharmacy alumni remained #1 among all UW schools in the number of alumni giving back to their home school or college. These many individual gifts—including PAA membership and scholarship gifts—demonstrate our collective commitment to nurturing a strong community of pharmacists and researchers.

To bring our community together this fall, the PAA has planned several fun events around Homecoming in October. We hope you’ll consider joining your UWSOP colleagues and friends at one, two, or all of the following gatherings:

• On October 14th, my wife Carrol and I are excited to host the School’s very first UW Husky Football Viewing Party. Join fellow football fanatics as we cheer our team on to victory against the Arizona Wildcats!

• On October 22nd, you can join Team #HuskyPharmacist for this year’s Alaska Airlines Dawg Dash on the UW Seattle campus. Run/walk with fellow alumni, friends, and students, and depart with a Brooks tech shirt, medal, and special UWSOP running swag. PAA Members receive $5 off registration with the discount code e-mailed in the September 6th PAA Member News.

• Swing by our no-host Homecoming Happy Hour Series to catch up with Puget Sound alumni and friends in Seattle (October 21st), Tacoma (October 25th), and Bothell (October 26th).

To register for these events, visit http://tinyurl.com/SOPhome17. We’d love to have you join us and encourage you to send any questions to rxalumni@uw.edu.

And of course, if you need to join or renew your PAA membership or make a PAA scholarship gift, now is a great time to do so online via tinyurl.com/joinpaa. Your membership makes our community possible. Thank you for your commitment to the UW School of Pharmacy!

Gary Harris, ’72, President, Pharmacy Alumni Association

Pharmacy Alumni Association (PAA) members and friends like you will proudly support three student scholarships this academic year—that’s a PAA record! To make a gift supporting additional PAA scholarships, go to:

sop.washington.edu/PAAFund
NEVER LET IT BE SAID THAT WE DO NOT AIM FOR THE STARS HERE AT THE UW SCHOOL OF PHARMACY! Our cover story this issue is the extraordinary and almost unimaginable innovation in kidney disease research. In late 2018, a box of 24 microphysiological kidney chips will be sent to the International Space Station for a series of research studies. The findings likely will lead to multiple breakthroughs in how we treat kidney disease and osteoporosis on Earth, reduce animal testing, predict adverse outcomes, and add to the evidence base for how we might send humans to Mars. Read more about this game-changing research led by Ed Kelly, Cathy Yeung, and Ken Thummel working in partnership with UW Medicine and Kidney Research Institute Director Jonathan Himmelfarb.

We remain focused on our core mission, thanks in large part to the outstanding commitment of our alumni and friends. Last Fall, the UW and UWSOP launched the public phase of our ambitious campaign and I am very pleased to share with you that our School’s endowment has crossed an important milestone: $22 million. I’m especially proud that this milestone was reached thanks to the collective commitment of our devoted alumni and friends--no single major gift got us there--it was the PAA memberships, Dean’s and President’s Club members, faculty endowments, student scholarships, and estate gifts together that made the difference.

While we have accomplished a great deal for our Campaign, we are not slowing our efforts toward reaching our campaign goals. We are in competition with our peer schools nationwide for the very best talent, from faculty to students to staff. We may be a bit of an underDawg, but I am confident in our ability to rise to the challenge.

If we haven’t seen you for a while, I invite you to find a time to join us at one or more of our upcoming School gatherings, events, and lectures. Your gifts of time and support allow us to go where no one has gone before.

Thank you and go DAWGS!

Sean D. Sullivan, BScPharm, Ph.D.
Professor and Dean, UW School of Pharmacy
In as early as 2018, a rocket carrying a payload that includes 24 microfluidic chips about the size of credit cards will transport an extraordinary UW kidney research project to the International Space Station. UW School of Pharmacy researchers Ed Kelly, Cathy Yeung, ‘05, and Ken Thummel, ‘87, along with Jonathan Himmelfarb, of UW Medicine and director of the Kidney Research Institute (KRI), in collaboration with the Seattle-based organ-on-a-chip company, Nortis, have been developing the “kidney-on-a-chip” as a laboratory model for understanding how this organ is affected by drugs, toxins and environmental exposures. The chips contain a central chamber lined with live kidney cells. This novel space medicine project is an attempt to understand how microgravity and other factors worsen kidney health. Researchers hope to use these discoveries to design better treatments for proteinuria (the presence of protein in the urine that signals possible kidney problems), osteoporosis (bone loss) and kidney stones on Earth. “By studying the kidney on a chip after a few weeks in space, we expect to learn more about how osteoporosis, kidney stones and other kidney conditions develop, which may lead to breakthroughs in treatment and prevention,” said Ed Kelly, also a KRI investigator. The first phase of the project will be to launch chips that measure the effect weightlessness has on healthy kidney cells. The second phase will launch about 18 months later and will measure the effect of weightlessness on diseased kidney cells. Astronauts on the space station will monitor and maintain the chips and then return them to Earth after several weeks for the UW team to examine. The kidney chips contain a small sample of live human kidney cells to test how drugs will affect those cells. The system offers a safer, more accurate, less invasive means of testing drugs before they are tried in patients. Importantly, it will reduce the need for animal testing in drug discovery research and is the foundation of research needed to send humans to Mars. “This study has the potential to improve the health of people living on Earth as well as prevent medical complications that astronauts experience from weightlessness,” said Jonathan. The kidney is a critical organ in drug clearance. When healthy, your two kidneys work together to filter about 110 to 140 liters of blood and produce about 1 to 2 liters of urine every day. Dehydration or diseases like diabetes and high blood pressure impair kidney function and result in serious medical conditions including protein in the urine and kidney stones. The kidney also plays a critical role in the body’s ability to use Vitamin D to maintain strong bones; a decline in this function can result in a loss of bone health. A better understanding of the mechanics of basic kidney function could lead to improved treatments for patients fighting kidney conditions. The Kidney on a Chip in Space Project will study effects of microgravity on the structure and function of the proximal and distal tubule microphysiological system. This model is used in laboratory studies to understand how the kidney clears drugs and how medications damage the kidney. In people, the kidney proximal and distal tubules are located in the nephron, which is the basic functional part of the kidney. They are both

**Kidney-on-a-chip will go to the International Space Station**

“Weightlessness is an accelerator. In the microgravity environment on the International Space Station, kidney problems are more common and develop in weeks or months, instead of decades—which accelerates our research and ability to find therapies to fight these conditions.”

---

**ED KELLY, ASSOCIATE PROFESSOR OF PHARMACEUTICS AND KIDNEY RESEARCH INSTITUTE INVESTIGATOR**
PharmD student leads shift from triage to evidence-based health care provider training in Ghana

David Nguyen, President of the UWSOP Global Brigades team, led a team of students, along with Institute for Innovation in Pharmacy Practice (I2P2) Endowed Clinical Professor Don Downing, to return to Ghana and advance the training program begun last year. Historically, Global Brigades programs bring health sciences students to under-resourced countries with the goal of providing a three or four day clinic to help people with acute conditions. In 2015, a team of about twenty students went to Panama to provide care to about 800 people in a matter of days. In three days, with that many patients, there is only so much that can be done: treat minor injuries and ailments, provide ibuprofen and vitamins, check vitals. Fourth year PharmD student David Nguyen was a part of the Panama team and he saw an opportunity to do more than triage. He wanted to train local health professionals to create a sustainable approach to the trips. Working with Don Downing and a team of faculty preceptors, David led the Global Brigades team in developing a program to teach the clinic’s nurses and physician assistants to recognize the signs and treat hypertension, the number one killer in Ghana. Last year, the team began this innovative approach in two clinics. This year, the team expanded into three clinics. PharmD student Job Pan created hypertension stage one and stage two flow charts following the current Ghanaian protocol and included the three most used medications in Ghana for hypertension in order to empower the nurses to identify and take action when therapy is suboptimal or lacking. “The most valuable thing that I learned was how to approach healthcare problems in rural communities of a developing country,” said David. “Like us, they face health care barriers like transportation and economic standing, but it is on a much larger scale in Ghana than here in the U.S.” Another team on-site brought a polaroid camera. “Everyone was excited and went home to put on their best clothing for their photo. I realized that they’ve never had a picture of themselves before. Sometimes it is the simple things—having a photo of your family—that change lives.” David hopes the team’s work enables nurses to screen for hypertension for each adult that visits the clinics; that the nurses will be more comfortable to advocate for their patients’ health; and have trained healthcare workers and other nurses to raise awareness about hypertension.

“Leading an entire group to another country and creating a new Brigade taught me more leadership skills than any other experience I’ve had. I couldn’t have done any of this without my team members.”

DAVID NGUYEN, 4TH YEAR PHARMD STUDENT

The Center for the Advancement of Science in Space (CASIS), the organization tasked by NASA to manage the International Space Station U.S. National Laboratory, will contribute the space flight, time in station, and Space Station crew costs, for an in-kind total of $8 million.
RECOGNIZING our donors

We gratefully acknowledge the many generous alumni, faculty, staff, students, corporations, foundations, and friends that made gifts and pledges to our School and made donations to student events between July 1, 2016 - June 30, 2017. Giving remains strong, with 12% of our alumni giving back to the School, making UWSOP #1 at UW in the percentage of alumni giving back to their School. Your gifts truly make a difference for our students, faculty and programs. Thank you!

INDIVIDUALS

$25,000+
Ryan & Keli Hansen
Phillip & Sandra Nudelman
John O’Connell Jr.
Peggy & David Odegard
Ryan & Jessica Oftebro
Elmer (D) & Joy Plein

$10,000-$24,999
David & Anita Bailey
Thomas & Kathleen Baillie
Lynn (D) & Geraldine (D) Brady
Claire & Andrew Forster
Florence Glibaldi
Rodney Ho & Lily Hwang-Ho
Sara Hurley & Matthew Thomlinson
Edward & Janet Kelly
Virginia Leland
Rene & Beloria Levy
Douglas & Yvonne Mendenhall
Danny & Barbara Shen
Shabir & Salma Somani
Kenneth & Peggy Thummel
Jennifer Wilson-Norton & Laurence Norton
Raymond Wilson & Cheryl Wright-Wilson
Edward & Kathleen Wong
H. Steve & Kathryn White

$5,000-$9,999
Louis & Frances Garrison Jr.
Gary & Carrol Harris
Mark & Pamela Holzheimer
Stephen & Kathy Kushner
Seann & Catrena Sullivan
Patricia & Walter Warden

$2,000-$4,999 (President’s Club)
Lara Andjelkovic & Jacob Connell
Kate & Carl Atienza
Anirban Basu
John & Gayle Bittinger
Herbert Bridge & Edith Hilliard
Brian Bullock
Weichao & Sandy Chen
Christopher & Maureen Endres
Michael & Margaret Faulkner
Sallie & Brett Hartnett
Paul & Chana Hiranaka
Mark Holodniy & RoseAnn Kushner
Kathleen Kaa
S. Cyrus Khojasteh
Ronald & Cherie Klein
Craig & Sally Kvam

Soraya Madani & Jon Eisenberg
Malcolm & Diane McCallum
Marla & Patrick Osinski
Scott & Ellen Ramsey
Beverly & Michael Schaefer
Andy & JoAnn Stergachis
Tom & Pamela Szikutak
Bettie Tomchak
Dara Uch
David & Julie Veenstra
Chris & Gail Whitley
Larry & Margaret Wienkers
Donald & Arda Williams

$1,000-$1,999 (Dean’s Club)
Kimberly Adkison
Leon Alzola
Gail & Arnold Anderson
Richard & Teresa Austin
Jonathan & Christina Campbell
Carol Chervenak & William Barish
Barry & Judith Christensen
Janet & William Corriston
Bonnie & Walter Davison
Karan & James Dawson
Beth Devine
Leslie Dickmann
Donald & Donna Dockter
Donald & Anne Downing
Jackie Gardner & Gary Elmer
Thomas Hazlet
Kirk Henne
Shiu-Lok Hu
Kay Humm
Christene & Anthony James
Brenda & Jess Kelly
Paul & Mary Kuehn
Linda & James Lang
Sze Lau
Randall & Lori Legg
Larry & Ellen Oliver
Mary Paine
Gregory & Gloria Pollock
C. Rene & David Porubek
James & Patricia Ramseth
Shelby & Steve Reed
Allan Rettie & Shannon Stewart
Natalie Ritchie & Joseph Zolnerciks
James & Diann Robbers
Joshua Roth & Meghan Glavin
Beverly & Glenn Sakuda
Arvind Thakkar
Herbert Tsuchiya
Bradley Wong
Roger & Marlene Woolf

$500-$999
Preeti Bajaj
Ronald & Kathleen Beil
George Benson, Jr.
Jennie Best
Jamiela Braxton
Ted Bruya
Josh & Amy Carlson
Kevin Coe
Karen Craddock
Michael Cundari
Stephanie Decker & George Guenther
Jamie Dunning
Tamara & Stephen Eide
Earl & Betty Fager
Steven & Kim Fijalka
Cameron Fosterling & Harry Schnepf II
Kelli Hatico
Lars Hennum (D)
Vivian & Jeffrey Hiroo
John & Maureen Horn
Daniel & Carolyn Jones
Andrea Kawakami
Bojan Lalovic
Minja & Young Lee
William Nichols & Patricia Richards
Miroslava & Ricardo Orozco
Dominic & Natalie Poon
Richard Ramsey & Shirley Scott
Lisa & Richard Reis
Robert & Martha Satterthwaite
Brian Seiki
James & Pamela Seymour
Vandana & J. Greg Satter
Julia Slejko
Ian Templeton & Allison Cougan
Paul Tom
Bruce Wang
Victor & Ann Warner
Mary Wingate

Every effort has been made to represent the names of our donors accurately. We apologize for any errors or omissions. Please send any corrections to rxalumni@uw.edu.
COPORATIONS & FOUNDATIONS

$50,000+
Allergan, Inc.
Amgen
Bayer AG
CTI BioPharma Corporation
Eli Lilly and Company
ERA Living
Harvard Medical School
Kaiser Permanente Medical Group
Kelley-Ross and Associates, Inc.
Mallinckrodt, Inc.
Seattle Institute for Biomedical & Clinical Research
Simcyp Limited
Southcentral Foundation
University of Pennsylvania
Yale University

$25,000-$49,999
Abbott Laboratories
AHF Pharmacy
Albertsons Stores Charitable Foundation, Inc.
AstraZeneca PLC
Bank of America Corporation
Bill & Melinda Gates Foundation
Bob Johnson's Pharmacy
Community Foundation of Snohomish County
CVS Caremark
Gilead Sciences, Inc.
InFaith Community Foundation
National Community Pharmacists Association Foundation
Network for Good
Odessa Drug
Pacific Real Estate LLC
PhRMA Foundation
Premera Blue Cross
Scholarship Foundation of Northshore
Starbucks Coffee Company
State of Washington

$10,000-$24,999
Microsoft Corporation
Pan Foundation
Tansna Therapeutics, Inc.
Walgreens

$2,500-$9,999
American College of Clinical Pharmacy Research Institute
The Bartell Drug Company
Electronic Arts, Inc.
Eli Lilly and Company
Fred Meyer, Inc.
Walter & Hazel Hinman Foundation
International Society for Pharmacoeconomics and Outcomes Research
Quality Food Centers (QFC) Inc.
Rite Aid Headquarters Corporation
Robert W. Baird & Company, Inc.
The Seattle Foundation
Valley Medical Center
Washington State Pharmacy Foundation
Electronic Arts, Inc.

$500-$2,500
Abbott Laboratories
AHF Pharmacy
Albertsons Stores Charitable Foundation, Inc.
AstraZeneca PLC
Bank of America Corporation
Bill & Melinda Gates Foundation
Bob Johnson's Pharmacy
The Boeing Company
Community Foundation of Snohomish County
CVS Caremark
Gilead Sciences, Inc.
InFaith Community Foundation
National Community Pharmacists Association Foundation
Network for Good
Odessa Drug
Pacific Real Estate LLC
PhRMA Foundation
Premera Blue Cross
Scholarship Foundation of Northshore
Starbucks Coffee Company
State of Washington

ADVANCING PHARMACY FOR WASHINGTON, FOR THE WORLD

The Campaign for the UW School of Pharmacy is well underway. The foundation for meeting our $50 million goal for UWSOP has been laid. We invite you to join us in these final stages of our ambitious campaign.

2016 CAMPAIGN FOR UWSOP LAUNCHED
2020 CAMPAIGN CONCLUDES

UWSOP ALUMNI ARE #1 AT THE UW FOR GIVING BACK TO THEIR SCHOOL/COLLEGE

$500K OUR STRETCH GOAL FOR SCHOLARSHIPS AWARDED ANNUALLY (2X AMOUNT AWARDED IN 2017)

$50M CAMPAIGN FOR UWSOP FUND RAISING GOAL

$22M UWSOP ENDOWMENT HITS MAJOR MILESTONE
UW School of Pharmacy ranks #9 in the world for pharmacy and pharmaceutical sciences (#3 for universities with a School of Pharmacy and #3 for US public universities), per Academic Ranking of World Universities. The ranking is based on faculty, student, and research staff productivity.

Ranita Patel, a pediatric nephrology research fellow in Ed Kelly’s Lab, received the John Mahan Best Abstract Award at the International Pediatric Nephrology Fellows meeting in Las Vegas for her study entitled “Utility of a Microphysiological 3D model of the Human Kidney Proximal Tubule for Predictive Toxicity Testing.”

Associate Professor of Pharmaceutics Nikki Klatt, with graduate student Ryan Cheu, and post doc Alex Zevin, had research published in Science magazine. Their paper titled, “Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women,” found that some types of bacteria could reduce the efficacy of the drug.


PORPP Associate Professor Beth Devine was selected to serve on the AcademyHealth Methods Council. The Council, comprising 21 members from multiple disciplinary perspectives in health services and policy research, advises the Board and AcademyHealth leadership on the priorities and trends in new methods and trainings for members and the field of Health Services Research.

Reader's Digest interviewed Assistant Professor & Kelley-Ross Faculty Fellow Jenny Bacci about polypharmacy complications in “11 silent signs your medications are making you sick.”

We extend hearty congratulations to our BRAMS faculty member Eric Hayashi on his great success in building his laboratory services company LabConnect, a R&D services company, that announced $24.5M Series A funding round.


Professor & Associate Dean Andy Stergachis and a global team of researchers found that artemisinin therapies are as safe as quinine for women in first trimester (published in PLoS Medicine).

Professor Emeritus Danny Shen received the Outstanding Mentor Award for his dedicated service to our graduate students. The Outstanding Mentor Award recognizes and encourages outstanding mentorship of graduate students by UWSOP faculty members. Danny Shen, PhD, is Professor Emeritus of Pharmaceutics and Pharmacy. Danny joined the School of Pharmacy faculty in 1984 and has amassed an outstanding record of graduate training that includes serving as the principal supervisor of 15 PhD recipients and as a member of the supervisory committee of at least 80 PhD and MS graduates within our School.

“Epilepsy has long been known to be a complex and heterogeneous disorder,” notes Harold Kohn. One of the main researchers behind multiple anti-epileptic (AEDs) drugs and significant advances in seizure disorder research is Pharmacy Department Chair H. Steve White. To honor his 40 year career and multiple breakthroughs, Neurochemical Research had a special issue focused on Steve’s work and influence in the field. Guest editor, Henrik Klitgaard, wrote, “Steve is not only unique by his scientific contributions and behavior, he is also one of the very rare scientists that have the good fortune to see their research materialize into new treatment options, improving patient’s lives, and generating hope for so many others.” Dean Sean D. Sullivan said, “What Steve has accomplished over the course of his career is extraordinary. We are proud to see his life’s work honored at this level.”
Don Downing receives ACA Award

The American College of Apothecaries presented the 2016-17 Albert E. Rosica, Jr. Memorial Award to UWSOP Institute for Innovation in Pharmacy Practice (I2P2) Clinical Professor Don Downing, ’75, at the College's 2017 Fall Pharmacy Conference at the Loews Philadelphia Hotel. The award, established in memory of Albert E. Rosica, Jr., a Past President of ACA, is presented each year to a pharmacy practitioner for his or her contributions to pharmacy education through participation in pharmacy clerkship programs, serving on various college committees, teaching, working with the alumni association, and making other contributions to academic programs. For the past forty years, Don has devoted his career as a professor and practitioner to moving the profession of pharmacy forward. Associate Dean Peggy Odegard, ’85, ’90, commended Don’s dedication to pharmacy. “Don exemplifies the meaning of teaching by example and is a major contributor to the professional development of our pharmacy graduates. He embodies a service attitude for his students and peers, kindly nudging each of us to become involved to improve access to services for those who are less fortunate. He reaches out with regular service to communities both locally and throughout the world to help those in need.”

Long is IPPE Preceptor of the Year

The Introductory Pharmacy Practice Experiences (IPPE) Preceptor of the Year is given every year by UW School of Pharmacy to recognize one preceptor who has consistently gone above and beyond expectations in precepting IPPE students. Congratulations to Steve Long, the 2017 Introductory Pharmacy Practice Experiences (IPPE) Preceptor of the Year Award winner! Steve was nominated by our IPPE students for his outstanding contribution to the educational development of future pharmacists. We are indebted to our dedicated and wonderful preceptors like Steve who act as role models and mentors and inspire our students to become patient advocates, innovators and future leaders. “Steve is a great example of a pharmacist who puts his patients first,” wrote one student. “The strong relationships he creates with his patients allow them to trust his counsel. Steve is a very approachable preceptor and was always available when I had questions. He was trusting in my abilities, but also was sure that I understood how to do everything that was expected of me. Overall, a very high quality preceptor!”

Winkler is APPE Preceptor of the Year

Congratulations to Todd Winkler who was named the 2017 Wayne A. Kradjan Excellence in Clinical Teaching Award winner! Over the past 3 years, Todd has precepted 28 students and consistently receives high scores from our students for his teaching abilities and their learning experience. “Todd trusted me and my ability as a future pharmacist to make my own decisions,” wrote one student. “When patients stopped by to fill medisets, I got to be in charge. I showed a few patients new to the process how to organize their medisets. These types of interactions built my confidence where before I may have been hesitant to jump into the scenario.” Good preceptors provide useful feedback and clear expectations. One student shared: “He made sure to tell me when I did a good job, which gave me so much confidence. It is so easy to give out criticism, but not everyone takes the time to give praise for a job well done.” Congratulations, Todd!
Nath lab team takes aim at Alzheimer’s

Alzheimer’s disease affects about 5 million Americans, a number projected to roughly triple by 2050. The urgency of this grave population health challenge is with Abhi Nath and his team of researchers every day as they seek new options to treat and manage Alzheimer’s and related diseases. The key appears to lie with a process called protein aggregation, which links Alzheimer’s, Parkinson’s, and Chronic Traumatic Encephalopathy (CTE)—a disease that affects people, such as military veterans and football players, who have suffered concussions or traumatic brain injury. “At the molecular level, particular proteins in the brain are misbehaving,” said Abhi. A major culprit in Alzheimer’s disease and CTE is a disordered protein called tau. “Proteins are supposed to fold like origami to function. When you have a misfolded protein, they tend to stick together—in the wrong way. That phenomenon of aggregation is the underlying cause of diseases like Alzheimer’s.” Understanding how the disease begins and what happens at a molecular level would lead to improved diagnostic tools and therapies, but it’s a major challenge because proteins like tau are very flexibly moving targets, making it hard to use traditional tools of structural biology. “Nothing in our current tool belt works well with these targets,” said Abhi. Instead, the team are developing new approaches, drawing on a variety of scientific disciplines in order to have the biggest long-term impact. Eri Nakatani-Webster, ’13, a KL2 scholar and post doc, is working to develop sophisticated mathematical models of protein aggregation that will make it easier to understand and predict how a drug or other binding partner will affect the process. Graduate student Hannah Baughman is deeply focused on understanding how disordered proteins interact with the body’s own defense mechanisms against protein aggregation: molecular chaperones. These molecular machines can recognize when a protein is misfolding and help it refold into its correct structure, which may lead to new ways of helping our bodies protect us from these diseases. Graduate student David Baggett’s computer models of tau can screen millions of compounds to identify new molecules capable of binding different stages in the aggregation pathway. In addition to accelerating the pace of drug discovery, David’s work could improve early diagnosis—a particularly important challenge in diseases like Alzheimer’s and CTE, where cognitive symptoms manifest well after the damage has been done at the cellular level and it may be too late to treat the illness. Graduate student Eleanor Vane is taking a counter-intuitive approach by investigating whether aggregation-prone proteins could actually play a beneficial role by controlling bacterial infections and fungal growth. “Here in Medicinal Chemistry, we take what we learn every day about the biophysics of misfolding proteins and connect that to improving human health,” shared Abhi. “It is incredibly hopeful and fulfilling work, with great promise.”

“We can manage symptoms, but we have a long way to go for a therapy for Alzheimer’s. It’s like playing Tetris with Jello—there are hundreds of thousands of chemicals that could fit tens of thousands of gaps and we are looking for the right match.”

ABHI NATH, ASSISTANT PROFESSOR OF MEDICINAL CHEMISTRY AND PLEIN CENTER FOR GERIATRIC PHARMACY RESEARCHER

“Alzheimer’s is such a challenging and scary disease. Any difference we can make there would mean so much—a lot of us have been affected and it’s only going to get worse as the population gets older,” remarks Abhi Nath (pictured right with David Baggett, left).
Infertility can be a physically, emotionally, and financially painful experience for couples wanting to have biologically-related children. If a couple has been unable to conceive naturally in a 12-month period, they are considered infertile. Next steps are typically expensive and painful tests for women to determine the cause of the problem, before a couple pursues assisted reproductive technology such as IVF and IUI. But all that may change thanks to newly minted UWSOP alumnus and physician John Amory, ’17. John has found a major breakthrough in men’s fertility, working with Nina Isoherranen and members of her lab. Ironically, the breakthrough came from John’s research into a male contraceptive medication. After years of researching how to reduce sperm counts, John hypothesized that perhaps there was a way to increase sperm counts. He decided it was time to research in-depth and enrolled in the Pharmaceutics master’s degree program. “If you are retinoic acid or Vitamin A deficient, male fertility is suppressed,” said Nina. “John hypothesized that if he could find a drug to increase intratesticular retinoic acid, it would increase men’s sperm counts and thereby the chance of conception.” It turns out there is an FDA-approved drug, Accutane, a prescription acne medication, that is a retinoic acid isomer and increases retinoic acid concentrations and men’s sperm counts. For his Pharmaceutics thesis research, John obtained an Investigational New Drug (IND) from the FDA to test his theory that Accutane could be used to treat male infertility by increasing sperm counts. Early results are very promising. From his pilot group of 19 men there are now five babies: three from spontaneous pregnancies and two from assisted conception (one additional pregnancy did not come to term). John wants to conduct further research to understand better why this drug intervention did not work for about a third of the patients. “There are no obvious reasons why it didn’t work in terms of ethnicity, age, weight or other common indicators,” he said, “so I am curious if there are other markers that might explain why.” His research has been accepted for publication and he plans to pursue a double blind placebo study to confirm the pilot test findings. John said earning his master’s in Pharmaceutics changed how he practices medicine and thinks about research. “I know a lot more about drug interactions than I did before, even as a seasoned physician. I have a greater appreciation for how hard it is to make a drug and bring it to market. We tend to take medications for granted,” he continued, “but there is a saying: ‘the miraculous nature of the mundane.’ To me, the idea you can take something as mundane as a pill and use it to treat a symptom or cure a disease—that’s a miracle.” John’s breakthrough findings have the promise of alleviating financial, emotional, and physical stress for many couples wanting to grow their families. If the early pilots bear fruit, the tests and treatment for male infertility could drastically reduce the costs and radically improve outcomes for fertility treatment.

Physician and Pharmaceutics alumnus John Amory finds breakthrough treatment for male infertility

Infertility can be a physically, emotionally, and financially painful experience for couples wanting to have biologically-related children. If a couple has been unable to conceive naturally in a 12-month period, they are considered infertile. Next steps are typically expensive and painful tests for women to determine the cause of the problem, before a couple pursues assisted reproductive technology such as IVF and IUI. But all that may change thanks to newly minted UWSOP alumnus and physician John Amory, ’17. John has found a major breakthrough in men’s fertility, working with Nina Isoherranen and members of her lab. Ironically, the breakthrough came from John’s research into a male contraceptive medication. After years of researching how to reduce sperm counts, John hypothesized that perhaps there was a way to increase sperm counts. He decided it was time to research in-depth and enrolled in the Pharmaceutics master’s degree program. “If you are retinoic acid or Vitamin A deficient, male fertility is suppressed,” said Nina. “John hypothesized that if he could find a drug to increase intratesticular retinoic acid, it would increase men’s sperm counts and thereby the chance of conception.” It turns out there is an FDA-approved drug, Accutane, a prescription acne medication, that is a retinoic acid isomer and increases retinoic acid concentrations and men’s sperm counts. For his Pharmaceutics thesis research, John obtained an Investigational New Drug (IND) from the FDA to test his theory that Accutane could be used to treat male infertility by increasing sperm counts. Early results are very promising. From his pilot group of 19 men there are now five babies: three from spontaneous pregnancies and two from assisted conception (one additional pregnancy did not come to term). John wants to conduct further research to understand better why this drug intervention did not work for about a third of the patients. “There are no obvious reasons why it didn’t work in terms of ethnicity, age, weight or other common indicators,” he said, “so I am curious if there are other markers that might explain why.” His research has been accepted for publication and he plans to pursue a double blind placebo study to confirm the pilot test findings. John said earning his master’s in Pharmaceutics changed how he practices medicine and thinks about research. “I know a lot more about drug interactions than I did before, even as a seasoned physician. I have a greater appreciation for how hard it is to make a drug and bring it to market. We tend to take medications for granted,” he continued, “but there is a saying: ‘the miraculous nature of the mundane.’ To me, the idea you can take something as mundane as a pill and use it to treat a symptom or cure a disease—that’s a miracle.” John’s breakthrough findings have the promise of alleviating financial, emotional, and physical stress for many couples wanting to grow their families. If the early pilots bear fruit, the tests and treatment for male infertility could drastically reduce the costs and radically improve outcomes for fertility treatment.

“The fact that we were able to overcome male infertility for six men in our small sample group, using a medication that is already on the market, shows great promise for couples wishing to conceive.”

DR. JOHN AMORY, M.S. ALUMNUS IN PHARMACEUTICS

Physician and Pharmaceutics alumnus John Amory finds breakthrough treatment for male infertility

Infertility can be a physically, emotionally, and financially painful experience for couples wanting to have biologically-related children. If a couple has been unable to conceive naturally in a 12-month period, they are considered infertile. Next steps are typically expensive and painful tests for women to determine the cause of the problem, before a couple pursues assisted reproductive technology such as IVF and IUI. But all that may change thanks to newly minted UWSOP alumnus and physician John Amory, ’17. John has found a major breakthrough in men’s fertility, working with Nina Isoherranen and members of her lab. Ironically, the breakthrough came from John’s research into a male contraceptive medication. After years of researching how to reduce sperm counts, John hypothesized that perhaps there was a way to increase sperm counts. He decided it was time to research in-depth and enrolled in the Pharmaceutics master’s degree program. “If you are retinoic acid or Vitamin A deficient, male fertility is suppressed,” said Nina. “John hypothesized that if he could find a drug to increase intratesticular retinoic acid, it would increase men’s sperm counts and thereby the chance of conception.” It turns out there is an FDA-approved drug, Accutane, a prescription acne medication, that is a retinoic acid isomer and increases retinoic acid concentrations and men’s sperm counts. For his Pharmaceutics thesis research, John obtained an Investigational New Drug (IND) from the FDA to test his theory that Accutane could be used to treat male infertility by increasing sperm counts. Early results are very promising. From his pilot group of 19 men there are now five babies: three from spontaneous pregnancies and two from assisted conception (one additional pregnancy did not come to term). John wants to conduct further research to understand better why this drug intervention did not work for about a third of the patients. “There are no obvious reasons why it didn’t work in terms of ethnicity, age, weight or other common indicators,” he said, “so I am curious if there are other markers that might explain why.” His research has been accepted for publication and he plans to pursue a double blind placebo study to confirm the pilot test findings. John said earning his master’s in Pharmaceutics changed how he practices medicine and thinks about research. “I know a lot more about drug interactions than I did before, even as a seasoned physician. I have a greater appreciation for how hard it is to make a drug and bring it to market. We tend to take medications for granted,” he continued, “but there is a saying: ‘the miraculous nature of the mundane.’ To me, the idea you can take something as mundane as a pill and use it to treat a symptom or cure a disease—that’s a miracle.” John’s breakthrough findings have the promise of alleviating financial, emotional, and physical stress for many couples wanting to grow their families. If the early pilots bear fruit, the tests and treatment for male infertility could drastically reduce the costs and radically improve outcomes for fertility treatment.

“The fact that we were able to overcome male infertility for six men in our small sample group, using a medication that is already on the market, shows great promise for couples wishing to conceive.”

DR. JOHN AMORY, M.S. ALUMNUS IN PHARMACEUTICS
In November 2015, The Washington Post reported that nearly 3 in 5 American adults take a prescription drug. Drug costs have been increasing over time, especially specialty drugs. A report from the Pew Charitable Trust showed the cost for specialty drugs used to treat autoimmune disease and cancer can be over $100,000 a year per person. There are now 300 specialty drugs approved, with 700 in development. With costs so high for these life-saving drugs, patients and their insurers want to know they are getting good value for their care. The research partnership between UW School of Pharmacy (UWSOP) and the Institute for Clinical and Economic Review (ICER) leverages UWSOP’s expertise in economic modeling of pharmaceutical interventions to support ICER’s growing body of work in new drug assessments. The UW team is comprised of faculty Josh Carlson (PI), David Veenstra, Anirban Basu, Lotte Steuten; staff scientists Greg Guzauskas and Marita Zimmermann; and a graduate student, Elizabeth Brouwer. The UWSOP’s Pharmaceutical Outcomes Research and Policy Program (PORPP) research team develops cost-effectiveness models for soon-to-be or recently FDA approved drugs, using evidence synthesis work performed by ICER, publicly-available data, and data from drug manufacturers. To date the UWSOP team has completed economic evaluations on 6 topics: multiple myeloma, non-small cell lung cancer (NSCLC), plaque psoriasis, multiple sclerosis, atopic dermatitis, and osteoporosis, and are currently working on an evaluation of voretigene neparvovec, a gene therapy for vision loss associated with biallelic RPE65-mediated retinal disease. Overall they found a number of drugs provided intermediate to high value for money according to ICER’s thresholds (dupilimab in atopic dermatitis, drugs used in plaque psoriasis (adalimumab, etanercept, infliximab, ustekinumab, brodalumab, ixekizumab, secukinumab and apremilast), tyrosin kinase inhibitors (erlotinib, gefitinib, and afatinib) in NSCLC, and alemtuzumab in multiple sclerosis). Other drugs for these conditions were generally considered to provide low value for money. Of note, daratumumab in multiple myeloma was subsequently found to provide good value for money according to ICER’s thresholds in a follow-on peer reviewed publication that included data that was not available during the initial review. The partnership has led to concrete results—in at least one case thus far, the team’s research was used to inform a manufacturer’s pricing considerations. Sanofi/Regeneron worked closely with the ICER team and health insurers to establish a value-based price for their new product, dupilimab, used to treat atopic dermatitis. Experiences like this can improve the health system and solidifies the key role health economists and outcomes researchers can play to bring more value to patients and our health care system. Long term, the use of decision modeling as part the evaluation of new medical products has the potential to inform patient care, improve our health care system and ensure that the cost of medical products is aligned with the value they provide.

“‘The UWSOP and ICER partnership has begun to show we can help improve patient care and the U.S. health care system by validating drug prices based on evidence and value.’”

Josh Carlson, Associate Professor of Pharmacy
UWSOP’s student team Iris To, Nina Kim, Derek Louie, and Andrew Nguyen (third year PharmD students) came in second at the national Academy of Managed Care Pharmacy (AMCP) Pharmacy & Therapeutics Competition. Competition is keen with 60 teams participating nationwide. Teams must review drugs for their hypothetical patients and create a dossier that looks at clinical trials, safety, and how the drug fits into therapy. Students research safety and perform an economic analysis for the patient’s benefit. UWSOP has had a finalist team most years over the past 12 years. Congratulations to Iris, Nina, Derek, and Andrew!

Third year PharmD student Sean Linn led the initiative for the 2017 Interprofessional Health Fair in Red Square. “I have a passion to serve and UWSOP gives me the training and confidence needed to do this successfully,” Sean shared. The event brought together 31 student and external health organizations and reached over 1,700 attendees. Working with first year PharmD and Outreach Liaison Hanna Kleiboeker, the two led the organizing and planning. “It was literally all grass roots, cold calls to the University, professors, organizations, and sponsors. I was proud of the willingness of all organizations and volunteers to serve our community.”

Theresa Aliwarga, a Medicinal Chemistry graduate student and researcher in Rheem Totah’s lab, was invited to do a podium presentation of her research on CYP2J2-mediated epoxyeicosatrienoic acids (EETs) as potential markers for cardiovascular disease at this summer’s Gordon Research Conference in Drug Metabolism. “I was able to show that a higher level of EETs is associated with lower risk of sudden cardiac arrest,” she said. “Cardiovascular disease remains the leading cause of mortality globally,” she stated. “If monitoring EET levels could be used to detect anomalies in the heart, it could prevent a lot of damage associated with cardiovascular disease.”

Lindsay Henderson chose to pursue a dual PharmD/PhD in Pharmaceutics to combine her interests in patient care and research: “I knew that if I came to UW, I would receive a prestigious education and learn from professors who want to see me succeed.” In Ken Thummel’s lab, she studies variation in warfarin pharmacogenes and its impact on drug disposition in the underrepresented Alaska Native and American Indian populations. She also serves as the Junior Communications Officer for ASPET’s Drug Metabolism & Disposition Division where her duties include attending Executive Committee meetings and preparing articles for ASPET’s quarterly news magazine, The Pharmacologist.

Theresa Aliwarga, a Medicinal Chemistry graduate student and researcher in Rheem Totah’s lab, was invited to do a podium presentation of her research on CYP2J2-mediated epoxyeicosatrienoic acids (EETs) as potential markers for cardiovascular disease at this summer’s Gordon Research Conference in Drug Metabolism. “I was able to show that a higher level of EETs is associated with lower risk of sudden cardiac arrest,” she said. “Cardiovascular disease remains the leading cause of mortality globally,” she stated. “If monitoring EET levels could be used to detect anomalies in the heart, it could prevent a lot of damage associated with cardiovascular disease.”
“We always knew our family was going to make a gift to the University of Washington School of Pharmacy,” said Cheri Ryan. “My Aunt Bette and Uncle Bryan always talked about this gift. It was so important to both of them to give back to his school.” Bryan and Bette Wallace’s gift is one of the largest in the history of the UW School of Pharmacy and will bolster the School of Pharmacy and support student pharmacists. “It’s hard to overstate the powerful impact the generous gift from the Wallaces will have on our students,” said UWOSP Dean Sean D. Sullivan. “One of my top priorities has been to attract and retain students who epitomize the intellect, innovation, and heart for which the UW School of Pharmacy has always been known.” Bryan Walker Wallace was born on February 10, 1916, ten miles south of Cornell, Washington. He graduated from Cornell High School in 1934, moving to Seattle to attend the University of Washington. He graduated with a degree in Bachelor of Science in Pharmacy on June 10, 1939, and became board certified by the State of Washington within days. Bryan’s pharmaceutical career began with the Walgreen Drug Company, working his first three years in Everett, Washington, followed by stints in Sacramento and Los Altos, California; Klamath Falls, Oregon; Redwood City, and again Los Altos, California. His wife, Elizabeth (Bette) Ruth (Stadler), was born on April 23, 1924 in Taylor Creek, Montana. Her family moved to Alderwood Manor, Washington in 1928. She graduated from Edmonds High School in 1942. Between 1942 and 1949 she worked as a civilian for the United States Army in Seattle, Alaska, and Tokyo, Japan. Shortly after her return to the States she met Bryan and they were married on June 24, 1950, in San Francisco, California. In 1953, he worked for Bartell Drug in Seattle before moving to Mountain View, California in 1954 where he and Bette opened their own drug store, Bryan’s Drug. Bette worked in the drug store with Bryan. In 1956, they purchased an additional store in Morgan Hill, California. They lived most their married life in Mountain View, California. The Morgan Hill store was sold after a couple of years but the Mountain View store was open until 1974. Their patients were transferred to Los Altos Pharmacy where Bryan continued to work part-time for several years until his retirement. After almost a fifty-year career as a pharmacist, Bryan passed away on December 28, 1989, in Mountain View, California. Just prior to Bryan’s passing Bette began working as a travel agent. She owned and managed several travel agencies that allowed her to travel the world until her retirement in the late 1990s. Bette passed away on December 4, 2016, at her home in Mountain View, California. Cheri said, “My Aunt never forgot the impact the School had on my uncle and she wanted to honor his wishes to support the School.” We are very grateful to Bryan, Bette, and their family for their generosity and deep commitment to the UWSOP.
UWSOP Dean’s Club leads the way for UWSOP

At this summer’s Dean’s Club event, Ron Klein, ’76, founding Dean’s Club member and Campaign Co-chair, shared the impact members have on UWSOP.

“I am honored to have been selected by Dean Sullivan to serve as one of the Campaign Co-chairs for the UWSOP. I wanted to say a few words to thank all of you for your membership in the Dean’s Club and to underscore the important work that we do. Twenty-six years ago, I joined a small but dedicated circle of fellow Pharmacy alumni to create the Dean’s Club. We wanted to preserve and further that excellence! Since then, our circle of supports has grown, and together we have accomplished a great deal by offering a high level of support to the School. We have increased scholarship and fellowship funding, supported innovative faculty efforts and much more. These achievements are truly a collective effort, and I am proud and grateful to celebrate them. As you may know, the UWSOP is currently engaged in an ambitious fund raising campaign. I feel that Dean’s Club members are an important part of this campaign. Your thoughtful gifts will make a difference in moving the School forward. We have the opportunity through this campaign to grow our numbers and our impact for students and the profession of Pharmacy. Speaking of gifts, did you know that you can double your contribution to the SOP, if your employer has a Matching Gift program? My former employer has generously matched all of my gifts to UW and to the UWSOP for 35 years. You may have the same opportunity! Please check with your employer about Matching Gifts and if you have a significant other, please check with their employer as well. I would like to thank all of you for your tremendous support of the SOP. Moving forward, I hope you will continue to join and encourage others to join this very special group of peers in support of the school of which we can all be proud. With boundless gratitude, thank you and I hope to see you again soon at future Dean’s Club or School events.”

RON KLEIN, ’76, CAMPAIGN CO-CHAIR, FOUNDING DEAN’S CLUB MEMBER

Porpp Student fund named after Penny Evans

Pharmaceutical Outcomes Research and Policy Program Director Anirban Basu announced the establishment of The Penny Evans UW International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Student Chapter Support Fund. This fund, named in honor of our highly-esteemed, award-winning program administrator, Penny Evans, will support student activities for our ISPOR chapter. Penny retired in June 2017, but her influence and excellence remain forever imprinted on our program—and are now encapsulated in this fund. The students and alumni of the PORPP program know first hand how important Penny has been to the growth and excellence of this globally-renowned program. “As we enter a new chapter in our evolution as a program,” says Anirban, “the Penny Evans ISPOR Student Chapter Support Fund will allow us to lead the way in fostering the exceptional talent and innovation of our students by supporting their professional development.” Incoming chapter president Nathaniel Hendrix shared, “Thanks to this fund, our chapter is able to become engaged with the wider health economics outcomes research community.”
1. My pharmaceutical sciences idol in the academy is UWSOP Sid Nelson Endowed Professor Bill Atkins, and Associate Professor Nina Isoherranen for their creativity. In the industry, I admire Marcel Hop, a deep thinker and an inspiring leader.

2. If I had unlimited funding, I would work to discover detection methods for catching cancer in earlier stages.

3. During my first year rotation, Wendel Nelson showed me how to perform hydrogenation reactions in Bagley Hall. His first words to me were: “When you are in the lab, assume something is going to go wrong, so make sure you tell others what you are going to do.” I thought this is a very wise idea.

4. I have several family members working in health care: my wife, Zarrin Ferdowsi, is an alumna of UW School of Dentistry and my sister is in health sciences at Johns Hopkins. My son Sohrob will start UW this Fall. My nephew, Bobak Ferdowsi, is also a UW alumnus. In 2012, he was the flight director at the Jet Propulsion Lab (JPL) involved in NASA’s Mars rover Curiosity. He became known as the “Mohawk Guy” and went viral on the internet.

5. I love watching football...both kinds. In fact, my most memorable trip was to Brazil for the World Cup.

6. I like my coffee with cream.

7. I have two favorite movies: A Town Like Alice and Cinema Paradiso. For fun, I love to read. My favorite book is One Hundred Years of Solitude by Gabriel Garcia Marquez.

Cyrus Khojasteh and Roger Woolf receive Distinguished Alumni Awards

Cyrus Khojasteh, ’98, chose to study Medicinal Chemistry at UWSOP after serendipitously attending a lecture by then Professor, now Dean Emeritus, Tom Baillie on acetaminophen mechanism of hepatotoxicity, drug induced liver injury, in the early 1990s. That lecture began a career in pharmaceutical science inspired by an interest in discovering innovative and safe medicine, a marriage of pharmacology and chemistry. Cyrus is an internationally recognized expert in drug metabolism and pharmacokinetics. His work in drug metabolism allows him to think about the chemistry of life and how a positive intervention is needed against a disease state. “Our bodies are designed to recognize and metabolize newly made chemicals not seen before,” he said. “By knowing one of the barriers (the drug metabolizing enzymes), how do we design and optimize molecules that are metabolically stable and minimize formation of reactive metabolites, which potentially can lead to toxicity.” Cyrus fondly remembers his PhD advisor and mentor former Dean Sid Nelson: “He taught me how to be a thoughtful researcher and nurture talents.” Sid used to hold group meetings for students on Friday afternoons. “It was at those meetings that I learned how to get to the point and be focused on key questions,” recalls Cyrus. And of course, after those group meetings, Sid would invite everyone to the College Inn. Cyrus remembers, “Some of the most complicated chemical reactions would be solved at the Pub but some reactions still remained a mystery the next day!”

“My advice to students is to explore and learn from the exceptional professors. When you graduate, stay connected to our school.”

Cyrus Khojasteh, UW SCHOOL OF PHARMACY ALUMNUS

“Leaders in Health Care”

Scott Herzog and Gary Harris of PAA present the Distinguished Alumni Award to Cyrus Khojasteh
ROGER WOOLF, ’85, is passionate about the leadership role pharmacists can have in the U.S. health care system. Growing up, many of his family members were in healthcare professions, including pharmacy. “My uncle was a pharmacist in Yakima,” he reflected. “Talking with him about his work helped me to see the potential impact pharmacists could have when they can be patient-focused.” In his position at Virginia Mason Medical Center, Roger provides leadership for a broad scope of pharmaceutical services within the Center’s integrated health care system. But he doesn’t stop there. He works diligently to teach and mentor student pharmacists to become leaders in health care and has been very committed to training UWSOP APPE/IPPE students and interns. “I always encourage students to get involved in leadership opportunities while in school. If we are to continue to advance the practice, we need people who can lead with passion, and not be afraid to try new and innovative ways for pharmacists to impact patient care.” He has maintained his connection with the UWSOP since completing his PharmD degree in 1985. “From the moment I was accepted to the UWSOP, I knew I was part of something special,” he said. “The faculty challenged us to be innovative and push a progressive practice. It was at UW that I really started my passion for advancing the practice.”

“...I am very appreciative of the training I received at the UW and am a strong advocate for the quality of education for which the School of Pharmacy is well known. To be personally recognized in this way is a real honor.”

ROGER WOOLF, UW SCHOOL OF PHARMACY ALUMNUS

Don Downing, Jeff Rochon, and many others, we were able to show the benefits to patients that come from having pharmacists as providers.” Now the team travels the U.S. sharing with providers and legislators how Washington led the way in advancing patient care by establishing pharmacists as full members of the health care team.

“I am very appreciative of the training I received at the UW and am a strong advocate for the quality of education for which the School of Pharmacy is well known. To be personally recognized in this way is a real honor.”

ROGER WOOLF, UW SCHOOL OF PHARMACY ALUMNUS

1. I have many pharmacy idols whom I strive to emulate. My strategy has always been to pull the best traits and take every advantage I can to be coached and mentored. There is always something new to learn and share with others.

2. People who show their commitment to the patient—especially when they can balance everything else and still make the best decision for the patient—are those I admire most.

3. I encourage students who intern with me to take advantage of any leadership opportunities that come their way, reminding them it will pay great dividends when they graduate.

4. I really like to travel and have been fortunate to spend time in both Europe and Japan. Each trip provides a new cultural experience and a different perspective on how we live our lives.

5. I make a point to visit pharmacies when I travel abroad. It gives me considerable insight into our own practice model and how fortunate we are. In one country, I needed a topical antibiotic, but the pharmacist could not help me without a script from a physician. In another country, the pharmacist could not dispense a cough suppressant without a script. It was surprising.

6. My favorite coffee is a custom drink called the Jolly Roger—a tall latte with Madagascar vanilla.

7. Being part of the UW School of Pharmacy and our highly-respected quality educational program is a big deal!
Congratulations to alumnus **Randy Elde**, ’72, ’11, who won the Washington State Diabetes Educator of the Year Award!


Congratulations to our first ever UWSOP Graduate Award recipients! **Jenny Sager**, PhD, ’16, won the award for Outstanding Dissertation for her dissertation, “Characterizing bupropion metabolism, pharmacokinetics and drug-drug interaction liability.” The UWSOP Outstanding Dissertation Award celebrates a graduate student who has conducted outstanding research at the doctoral (PhD) level. Her PhD advisor, Associate Professor of Pharmaceutics **Nina Isoherranen**, said “having mentored many outstanding graduate students, Jenny is one of the very best in her dedication, creativity, commitment to science and analytical ability.” Jenny is now a scientist with Vertex Pharmaceuticals, Boston, MA. Current students **Elijah Weber**, Pharmaceutics, **Mark Bounthavong**, PORPP, and **Ryan Seguin**, Medicinal Chemistry, won awards for Graduate Student Leadership.

**Faye (Zufei) Zhang**, ’17, now at Merck, has published “Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses” in *Drug Metabolism and Disposition*. *Journal of the American Pharmacists Association* (JAPhA) published a special issue entitled “Opioids, Naloxone, and Beyond: The Intersection of Medication Safety, Public Health, and Pharmacy,” which included work by several UWSOP faculty, students, and alumni. Faculty members **Josh Akers** and **Ryan Hansen**, ’03, with alumnus **Ryan Oftebro**, ’03, published, “Implementing take-home naloxone in an urban community pharmacy.”

**William “Bill” Howald** passed away August 14, 2017 in Salem, Oregon at the age of 76 after a brief illness. After retirement, Bill and his wife Carole moved to Oregon to be closer to family. Bill joined the School of Pharmacy, Department of Medicinal Chemistry as a Research Technologist working in the Mass Spectrometry Facility. He became the Manager of the Facility and Lecturer in Medicinal Chemistry in 1983 and retired in 2008 after building a world class center. During his tenure the Mass Spectrometry Center provided cutting edge mass spectrometers and other tools to support the diverse and evolving research programs in proteomics, drug metabolism and biochemical toxicology in the School of Pharmacy as well as the in the larger UW research community. He played an essential role in the research productivity of the school working closely with **Bill Trager**, Tom Baillie, Sid Nelson, Allan Rettie, Rene Levy, Ken Thummel and countless others. Perhaps equally significant to the mountains of his research accomplishments was the extensive hands-on training that Bill provided to the many generations of graduate students and post-doctoral fellows that have moved through our training programs. These scientists, now spread through the world, provide a long and lasting testimony to Bill’s legacy. Mass spectrometers are expensive, powerful, and unfortunately highly temperamental instruments. Medicinal Chemistry department chair **Kent Kunze** said, “Training new students required the endless patience and a good sense of humor for which Bill was famous. Bill was a consummate scientist and wonderful colleague and friend to all.” The family has asked that gifts in remembrance of Bill’s life and work be made to the William Howald Mass Spectrometry Support Fund at the UW School of Pharmacy at http://bit.ly/BHowald.
A wonderful evening brought together alumni and friends in Portland, Oregon, to share in great wines and even better conversation (L to R: Alisha Finke, ’11, Nick Finke, Danielle Massie, ’09, [front]and Carly Rodriguez , ’11).

UW School of Pharmacy showed their Purple Pride at the scholarship fund raising event (L to R: Jennifer Danielson, Armen Khachatourian, ’11, Sean D. Sullivan, Jacques Bouchy)

It was standing room only at the most popular Dean's Recognition Reception in UWSOP history! (Facing L to R: Bev Schaefer, ’70, and Gary Harris, ’72)

Dean's Club members enjoyed a special night at the Mariners Baseball game. (L to R: Dick Ramsey, ’55, Gary Harris, Lori Legg, and Randy Legg, ’02)

A wonderful evening brought together alumni and friends in Portland, Oregon, to share in great wines and even better conversation (L to R: Alisha Finke, ’11, Nick Finke, Danielle Massie, ’09, [front]and Carly Rodriguez , ’11).
The Phil and Sandra Nudelman Endowed Lecture series showcases the leadership, management, communication, and entrepreneurship that have been characteristic of Phil’s career as a leader in pharmacy and management.

STEVE DAVIS, CEO AND PRESIDENT OF PATH

This year’s Nudelman Endowed Lecture will be given by Steve Davis, CEO and President of PATH. Mr. Davis combines extensive experience as a technology business leader, global health advocate, and social innovator to accelerate great ideas and bring lifesaving solutions to scale. He currently is a member of the Council on Foreign Relations, serves on the board of InterAction, Challenge Seattle and sits on several advisory groups, including as a trustee of the World Economic Forum’s Global Health Challenge, on the stakeholder advisory panel for the global insurance and asset management firm AXA, and on the advisory board for Medtronic Labs.

THURSDAY, NOVEMBER 9, 2017, 6 PM
LYCEUM, HUSKY UNION BUILDING (HUB), UW-SEATTLE
FOLLOWED BY RECEPTION WITH APPETIZERS